← ANALYSTS · TIPRANKS
Jeet Mukherjee · BTIG
Hits
63%
62 of 99 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+26.2%
Over a year after the rating, TipRanks’ measure
Our companies rated now
16
Buy / hold / sell: 15 / 1 / 0
Upside of the analyst’s targets
+185.9%
Average over 15 current targets, to the last price
The market’s answer to the ratings
+7.1%
Day-0 move against SPY in the rating’s direction, average over 7 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 14on TipRanks Oct 15 06:10 | VSTMIWMVerastem · $836M | Reiterated | Buy | $24.00 | +177.5% | +4.6%next day +19.4% | ↗ |
| Oct 14on TipRanks Oct 15 06:10 | IBRXIWMImmunityBio · $10.5B | Reiterated | Buy | $12.00 | +30.7% | +2.2%next day +0.6% | ↗ |
| Oct 12on TipRanks 17:58 | PVLAIWMPalvella Therapeutics · $1.8B | Reiterated | Buy | $215 | +78.7% | −4.4%next day −3.5% | ↗ |
| Oct 6on TipRanks Oct 7 05:25 | AVBPIWMArriVent BioPharma, Inc. · $828M | Reiterated | Buy | $42.00 → $29.00−31.0% | +74.1% | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Oct 5on TipRanks 09:10 | VSTMIWMVerastem · $836M | Reiterated | Buy | $18.00 | +108.1% | +3.2%next day −3.7% · 5 days +2.7% | ↗ |
| Oct 1on TipRanks 16:45 | FHTXIWMFoghorn Therapeutics · $112M | Downgrade | Hold | — | — | −31.6%next day −1.7% · 5 days −2.2% | ↗ |
| Sep 23on TipRanks 06:15 | ORICIWMOric Pharmaceuticals · $1.3B | Initiated | Buy | $26.00 | +110.5% | −0.5%next day −1.0% · 5 days +1.7% | ↗ |
| Sep 22on TipRanks Sep 23 05:55 | VKTXViking Therapeutics · $3.4B | Reiterated | Buy | $125 | +396.6% | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Sep 17on TipRanks Sep 18 06:55 | IPHAInnate Pharma · $176M | Reiterated | Buy | $9.00 | +529.4% | −6.1%next day −0.7% · 5 days −11.8% | ↗ |
| Sep 13on TipRanks 21:20 | FTHFaeth Therapeutics · $517M | Reiterated | Buy | $55.00 | +192.6% | +4.9%next day −9.1% · 5 days −16.7% | ↗ |
| Aug 20on TipRanks Aug 21 10:06 | AAPGAscentage Pharma Group International Unsponsored ADR · $1.4B | Reiterated | Buy | $48.00 | +212.3% | −3.1%next day −2.3% · 5 days +7.0% | ↗ |
| Aug 12on TipRanks Aug 13 06:25 | AVBPIWMArriVent BioPharma, Inc. · $828M | Reiterated | Buy | $42.00 | +152.1% | 0.0%next day −5.3% · 5 days −4.1% | ↗ |
| Aug 12on TipRanks 16:05 | MNPRIWMMonopar Therapeutics Inc · $482M | Reiterated | Buy | $117 → $133+13.7% | +92.0% | −4.6%next day +2.6% · 5 days +2.4% | ↗ |
| Aug 12on TipRanks 07:30 | BCAXIWMBicara Therapeutics Inc. · $1.2B | Reiterated | Buy | $28.00 → $39.00+39.3% | +132.4% | +3.4%next day −4.8% · 5 days +5.4% | ↗ |
| Aug 11on TipRanks 06:55 | CATXIWMPerspective Therapeutics · $267M | Reiterated | Buy | $14.00 | +545.2% | +6.3%next day +2.3% · 5 days +1.3% | ↗ |
| Aug 6on TipRanks Aug 7 07:10 | FHTXIWMFoghorn Therapeutics · $112M | Reiterated | Buy | $11.00 | +494.6% | +14.3%next day +8.4% · 5 days +15.3% | ↗ |
| Aug 6on TipRanks Aug 7 07:10 | VSTMIWMVerastem · $836M | Reiterated | Buy | $18.00 | +108.1% | +0.8%next day +13.4% · 5 days +11.6% | ↗ |
| Aug 4on TipRanks Aug 5 06:25 | PVLAIWMPalvella Therapeutics · $1.8B | Reiterated | Buy | $215 | +78.7% | +6.2%next day +2.1% · 5 days +1.6% | ↗ |
| Aug 4on TipRanks Aug 5 06:25 | IBRXIWMImmunityBio · $10.5B | Reiterated | Buy | $12.00 | +30.7% | −4.6%next day +4.5% · 5 days +9.5% | ↗ |
| Jul 1on TipRanks 07:53 | NRIXIWMNurix Therapeutics · $2.7B | Assigned | Buy | $30.00 → $32.00+6.7% | +31.0% | −1.3%next day +0.4% · 5 days +2.5% | ↗ |
| Jun 25on TipRanks Jun 26 06:15 | KYMRIWMKymera Therapeutics · $9.0B | Reiterated | Buy | $134 | +27.9% | +16.5%next day −6.4% · 5 days −4.0% | ↗ |
| May 13on TipRanks 07:30 | ARVNIWMArvinas Holding Company · $468M | Reiterated | Buy | $16.00 → $18.00+12.5% | +158.2% | +2.6%next day −5.3% · 5 days −7.7% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗